EHA2026レポート⑥ 注目演題

小児高リスクB-ALLにおいて、
高強度化学療法2コースのブリナツモマブへの置換は
毒性を軽減しEFSを改善 REPLACEMENT OF HIGH DOSE COMBINATION CHEMOTHERAPY WITH BLINATUMOMAB IN NEWLY DIAGNOSED PEDIATRIC HIGH-RISK B-CELL ALL IMPROVED EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 AIEOP-BFM ALL 2017 TRIAL (#S103)

Martin Schrappe（University Medical Center Schleswig-Holstein, Campus Kiel, Pediatric Hematology and Oncology, ALL-BFM Study Group, Kiel, Germany）